340 related articles for article (PubMed ID: 28508455)
1. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms.
Cho S; Kwon SS; Lee KW; Yoo TK; Shin DG; Kim SW; Bae JH; Choi H; Kim YH
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28508455
[TBL] [Abstract][Full Text] [Related]
2. Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms.
Shin YS; Zhang LT; Zhao C; Kim YG; Park JK
Clin Interv Aging; 2014; 9():1021-30. PubMed ID: 25031529
[TBL] [Abstract][Full Text] [Related]
3. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an α-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial.
Kim TH; Jung W; Suh YS; Yook S; Sung HH; Lee KS
BJU Int; 2016 Feb; 117(2):307-15. PubMed ID: 26305143
[TBL] [Abstract][Full Text] [Related]
5. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
Takeda M; Nishizawa O; Gotoh M; Yoshida M; Takahashi S; Masumori N
Urology; 2013 Oct; 82(4):887-93. PubMed ID: 23953605
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment for male lower urinary tract symptoms with anticholinergic and alpha-blockers.
Gomelsky A; Kelly EF; Dalton DC
Curr Opin Urol; 2018 May; 28(3):277-283. PubMed ID: 29432226
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis.
Kim HJ; Sun HY; Choi H; Park JY; Bae JH; Doo SW; Yang WJ; Song YS; Ko YM; Kim JH
PLoS One; 2017; 12(1):e0169248. PubMed ID: 28072862
[TBL] [Abstract][Full Text] [Related]
10. Long-term alpha-blockers and anticholinergic combination treatment for men with lower urinary tract symptoms in real-life practice.
Bae WJ; Bae JH; Choi YS; Kim SJ; Cho HJ; Hong SH; Kim SW; Hwang TK; Lee JY
Int Urol Nephrol; 2012 Aug; 44(4):1077-84. PubMed ID: 22528586
[TBL] [Abstract][Full Text] [Related]
11. Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms.
Bae WJ; Bae JH; Kim SW; Chung BH; Kim JH; Kim CS; Lee HM; Lee KS; Yoo TK; Kim SI; Byun SS; Lee JY
J Urol; 2013 Jul; 190(1):180-6. PubMed ID: 23357213
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.
Lojanapiwat B; Permpongkosol S
Int Braz J Urol; 2011; 37(4):468-76. PubMed ID: 21888698
[TBL] [Abstract][Full Text] [Related]
14. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.
Verheggen BG; Lee R; Lieuw On MM; Treur MJ; Botteman MF; Kaplan SA; Trocio JN
J Med Econ; 2012; 15(3):586-600. PubMed ID: 22332704
[TBL] [Abstract][Full Text] [Related]
15. [Interest of a systematic assessment of the treatment of the lower urinary tract symptoms in the management of benign prostatic hypertrophy in general practice (1380 patients) - Study EVALURO].
Descazeaud A; Coloby P; De La Taille A; Kouri G; Mallet R; Rossi D; Rozet F; Zerbib M; Carrois F
Prog Urol; 2019 Feb; 29(2):116-126. PubMed ID: 30665818
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
17. Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study.
Yokoyama O; Tsujimura A; Akino H; Segawa N; Tamada S; Oguchi N; Kitagawa Y; Tsuji H; Watanabe A; Inamoto T; Shimizu N; Fujiuchi Y; Katsuoka Y; Azuma H; Matsuda T; Namiki M; Uemura H; Okuyama A; Nonomura N; Fuse H; Nakatani T
World J Urol; 2015 May; 33(5):659-67. PubMed ID: 25224929
[TBL] [Abstract][Full Text] [Related]
18. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study.
Takeda M; Yokoyama O; Yoshida M; Nishizawa O; Hirata K; Nakaoka R; Takita Y; Murakami M
Int J Urol; 2017 Jul; 24(7):539-547. PubMed ID: 28556284
[TBL] [Abstract][Full Text] [Related]
20. Comparison of add-on medications for persistent storage symptoms after α-blocker treatment in BPH patients - a network meta-analysis.
Su YT; Chen HL; Teoh JY; Chan VW; Wu WJ; Lee HY
BMC Urol; 2023 Oct; 23(1):154. PubMed ID: 37789333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
